Stanley Cohen, MD

Stanley Cohen, MD

Clinical Professor
Department of Internal Medicine
UT Southwestern Medical Center
Co-Director of the Division of Rheumatology
Presbyterian Hospital
Dallas, Texas

Related Videos

Based on your current assessment of anti-TNF biosimilars, what is the optimal trajectory of these agents in the setting of RA and related immune-related conditions? Video

Based on your current assessment of anti-TNF biosimilars, what is the optimal trajectory of these agents in the setting of RA and related immune-related conditions?

Based on your current assessment of anti-TNF biosimilars, what is the optimal trajectory of these agents in the setting of RA and related immune-related conditions?

How should rheumatologists and pharmacists make clinical decisions when choosing between biosimilars and their reference biologic agents in the setting of RA, AS, psoriatic arthritis and related conditions? Video

How should rheumatologists and pharmacists make clinical decisions when choosing between biosimilars and their reference biologic agents in the setting of RA, AS, psoriatic arthritis and related conditions?

Based on the available data for clinical equivalency and switching, can you discuss how rheumatologists and pharmacists should make clinical decisions when choosing between biosimilars and their reference biologic agents in the setting ...

Can you explain current policy as it relates to biosimilars, including considerations that apply to interchangeability for anti-TNF biosimilars and product naming guidelines? Video

Can you explain current policy as it relates to biosimilars, including considerations that apply to interchangeability for anti-TNF biosimilars and product naming guidelines?

Can you explain current policy guidance as it relates to biosimilars, including considerations that do or do not apply to interchangeability for anti-TNF biosimilars and product naming guidelines? What is the threshold for interchangeability?

When aessessing the rationale for switching from an originator anti-TNF to a biosimilar, single switch data is convincing for efficacy, safety, and comparable immunogenicity of the ant-TNF biosimilar. In what situations might "multiple switching" apply? Video

When aessessing the rationale for switching from an originator anti-TNF to a biosimilar, single switch data is convincing for efficacy, safety, and comparable immunogenicity of the ant-TNF biosimilar. In what situations might "multiple switching" apply?

When trying to assess the data and clinical rationale for switching from an originator anti-TNF to a biosimilar, it appears that the single switch data is convincing in supporting the efficacy, safety, and comparable immunogenicity of ...

What have we learned about the equivalency and outcome-based efficacy of biosimilars within the context of a "single switch" between the originator and biosimilar, including the NOR-SWITCH study? Video

What have we learned about the equivalency and outcome-based efficacy of biosimilars within the context of a "single switch" between the originator and biosimilar, including the NOR-SWITCH study?

What have we learned about the equivalency and outcome-based efficacy of biosimilars within the context of a “single switch” between the originator and biosimilar, including the NOR-SWITCH study; and what are the implications for clinical practice?

Can you compare clinical efficacy/equivalency and adverse side effects that have been reported with administration of the anti-TNF biosimilar versus the originator product, infliximab? Video

Can you compare clinical efficacy/equivalency and adverse side effects that have been reported with administration of the anti-TNF biosimilar versus the originator product, infliximab?

Can you compare, based on published RA trials, both the clinical efficacy/equivalency and adverse side effects that have been reported with administration of the anti-TNF biosimilar versus the originator product, infliximab? And how do ...

Can you discuss and explain recent clinical evidence focused on anti-TNF inhibitor biosimilars for infliximab in the setting of RA; and by extrapolation, AS, IBD, and related conditions? Video

Can you discuss and explain recent clinical evidence focused on anti-TNF inhibitor biosimilars for infliximab in the setting of RA; and by extrapolation, AS, IBD, and related conditions?

Can you discuss and explain the study design, rationale, results, and practical clinical implications of the most recent clinical evidence focused on anti-TNF inhibitor biosimilars for infliximab in the setting of RA; and by extrapolation, ...

How do regulatory approval and evaluation processes for biosimilars differ from those used for small-molecule generic medications? Video

How do regulatory approval and evaluation processes for biosimilars differ from those used for small-molecule generic medications?

How do regulatory approval and evaluation processes for biosimilars differ from those used for small-molecule generic medications? Can you differentiate these processes based on the specific steps of the approval process; including structural ...

How do regulatory approval and evaluation processes for biosimilars differ from those used for small-molecule generic medications? Video

How do regulatory approval and evaluation processes for biosimilars differ from those used for small-molecule generic medications?

How do regulatory approval and evaluation processes for biosimilars differ from those used for small-molecule generic medications?